Skip to content

Vincristine Liposomal

Published: July 26, 2026Updated: July 26, 2026

Marqibo is a liposomal formulation of vincristine sulfate, a vinca alkaloid chemotherapy agent. It is specifically indicated for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) who have relapsed or progressed after two or more prior lines of antileukemia therapy. This medication is administered intravenously by healthcare professionals in appropriate clinical settings.

Quick summary

Marqibo is a chemotherapy drug used to treat adults with relapsed or refractory acute lymphoblastic leukemia.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

RxNorm
1304996
Generic
Marqibo
Class
brand-name
Brands
—
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Marqibo is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse, or whose disease has progressed after two or more lines of antileukemia therapy.

Marqibo contains vincristine sulfate encapsulated in liposomes. Vincristine binds to tubulin and inhibits microtubule assembly, disrupting mitotic spindle formation and causing cell cycle arrest at metaphase, which leads to cell death in rapidly dividing cancer cells.

For adult use only. Administered as an intravenous infusion. The liposomal formulation has different pharmacokinetics than standard vincristine, so dosing is specific to this product. Should only be handled and administered by healthcare professionals trained in safe handling and administration of cytotoxic chemotherapy agents.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy